Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study

OBJECTIVES: Bimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourne, Rupert Richard Alexander, Kaarniranta, Kai, Lorenz, Katrin, Traverso, Carlo Enrico, Vuorinen, Jouni, Ropo, Auli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500185/
https://www.ncbi.nlm.nih.gov/pubmed/30944129
http://dx.doi.org/10.1136/bmjopen-2018-024129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500185/
https://www.ncbi.nlm.nih.gov/pubmed/30944129
http://dx.doi.org/10.1136/bmjopen-2018-024129

Ejemplares similares